Peptide conjugates of therapeutically used antitubercular isoniazid—design, synthesis and antimycobacterial effect
Authors:
- 24 March 2009
- journal article
- research article
- Published by Wiley in Journal of Peptide Science
- Vol. 15 (5) , 385-391
Abstract
Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis, a slow‐growing, powerful human pathogen which can survive in the host macrophages. In the chemotherapy of such intracellular pathogens it is necessary to achieve relatively high level of the drug in blood to attain therapeutically effective concentration in infected cells, which presumably has several serious side effects on healthy tissues. The elimination of M. tuberculosis from infected phagocytes could be more efficient with target cell‐directed delivery of antituberculars. A particularly promising approach is to conjugate a drug moiety to a peptide based carrier. The conjugates are chemically constructed to target release by hydrolysis (enzymatic and/or chemical) to liberate the active compound. Here we report the synthesis, characterisation and antimycobacterial evaluation of isoniazid (INH) peptide conjugates. As carrier moiety T‐cell epitope of immundominant 16‐kDa protein of M. tuberculosis and tuftsin‐derived peptides were used. To conjugate INH two synthetic methods were developed, where INH was coupled directly to the peptides or through a heterobifunctional reagent. We found that all of the INH conjugates were effective against M. tuberculosis and the minimal inhibitory concentration (MIC) values were comparable to the free INH moiety. Copyright © 2009 European Peptide Society and John Wiley & Sons, Ltd.Keywords
This publication has 36 references indexed in Scilit:
- HLA-DM Mediates Epitope Selection by a “Compare-Exchange” Mechanism when a Potential Peptide Pool Is AvailablePLOS ONE, 2008
- Binding of the anti‐tubercular drug isoniazid to the arylamine N‐acetyltransferase protein from Mycobacterium smegmatisProtein Science, 2005
- The mannose receptor: linking homeostasis and immunity through sugar recognitionTrends in Immunology, 2005
- Tuftsin: On the 30-year anniversary of Victor Najjar’s discoveryPeptides, 1999
- CAPTURE AND PROCESSING OF EXOGENOUS ANTIGENS FOR PRESENTATION ON MHC MOLECULESAnnual Review of Immunology, 1997
- Peptide partners call the tuneNature, 1994
- STRUCTURES AND FUNCTIONS OF MULTILIGAND LIPOPROTEIN RECEPTORS: Macrophage Scavenger Receptors and LDL Receptor-Related Protein (LRP)Annual Review of Biochemistry, 1994
- Tuftsin, A Natural Activator of Phagocyte Cells: An OverviewaAnnals of the New York Academy of Sciences, 1983
- Color test for terminal prolyl residues in the solid-phase synthesis of peptidesAnalytica Chimica Acta, 1980
- The characteristics, isolation and synthesis of the phagocytosis stimulating peptide tuftsinBiochemical and Biophysical Research Communications, 1972